Open AccessAnti-leukemic activity of phosphoproteins from Sesamin via induction of nuclear antigen H731and CLIP-associating protein 2 isoform X25 mediated apoptosis
Author(s) -
Pattharin Wannapruk,
Atchara Paemanee,
Sittiruk Roytrakul,
Dalina Tanyong
Publication year - 2017
Publication title -
international journal of phytomedicine
Language(s) - English
Resource type - Journals
ISSN - 0975-0185
DOI - 10.5138/09750185.2078
Subject(s) - sesamin , apoptosis , viability assay , chemistry , mtt assay , leukemia , microbiology and biotechnology , cancer research , pharmacology , biology , biochemistry , immunology , food science
Leukemia is an uncontrolled proliferation hematopoietic cancer cells that commonly treats with conventional therapies such as chemotherapy. However, many side effects were reported. Alternative medicines have been developed by using natural or herb compounds as therapeutic drug. Sesamin, a class of phytoestrogen isolated from sesame seed displaying potent anticancer activity in vitro and in vivo .However, the mechanism by which sesamin mediates anticancer effects on leukemic cells are notfully understood. In thisstudy, the effects of sesamin on cell viability, cell apoptosis and expression of phosphoproteins in Molt-4 and NB4 leukemic cell lines were investigated using MTT assay, flow cytometry and immobilized metal affinity chromatography (IMAC) phosphoprotein enrichment and LC-MS, respectively. The results showed that sesamin reduced viability and induced apoptosis in leukemic cells. In addition, 79 phosphoproteins were identified from LC-MS within three main clusters including biological regulation, cellular processand metabolic process. Interestingly, nuclear antigen H731 (PDCD4) and CLIP-associating protein 2 isoform X25 (CLASP2) showed increased in sesamin treated cells and associated protein-ligand interaction network with allicin, capsaicin, cucurbitacin B, and rapamycin which are known to activate apoptosis in cancer cells .Then, sesamin could be developed as candidate of alternative leukemia treatment in the future.